Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | NAT1 | P18440 | 7/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | MYC | P01106 | 1/20 | 0.55 |
| ▸ | MAX | P61244 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.54 |
| ▸ | MMP3 | P08254 | 2/20 | 0.53 |
| ▸ | MMP13 | P45452 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16762257 | 1.00 | PIM1 (0.61) | PIM1MEN1RAB9AKMT2ANAT1 | |
| SCHEMBL16762254 | 1.00 | PIM1 (0.61) | PIM1MEN1RAB9AKMT2ANAT1 | |
| SCHEMBL16762221 | 0.85 | XDH (0.53) | PIM1MEN1RAB9AKMT2ACISD1 | |
| SCHEMBL16762223 | 0.85 | XDH (0.53) | PIM1MEN1RAB9AKMT2ACISD1 | |
| SCHEMBL16998370 | 0.80 | RAB9A (0.37) | PIM1MEN1RAB9AKMT2ANAT1 | |
| SCHEMBL16787484 | 0.77 | MEN1 (0.59) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL16987573 | 0.77 | MEN1 (0.59) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL16987574 | 0.77 | MEN1 (0.59) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1250382 | 0.76 | PIM1 (1.00) | PIM1MEN1RAB9AKMT2ANAT1 | |
| SCHEMBL1250384 | 0.76 | PIM1 (1.00) | PIM1MEN1RAB9AKMT2ANAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022255411-A1 | METHOD FOR ENHANCING INNATE IMMUNE RESPONSE | 国立大学法人京都大学 | 2022-12-08 | — | — | WO | disclosed |
| EP-2881397-B1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | UNIV KYOTO (JP) | 2020-09-02 | — | — | EP | disclosed |
| EP-2881397-B1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | UNIV KYOTO (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-10017524-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2018-07-10 | — | — | US | disclosed |
| US-10017524-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2018-07-10 | — | — | US | disclosed |
| US-10017524-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20170355715-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2017-12-14 | — | — | US | disclosed |
| US-20170355715-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2017-12-14 | — | — | US | disclosed |
| US-20170355715-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2017-12-14 | — | — | US | disclosed |
| US-9745323-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2017-08-29 | — | — | US | disclosed |
| US-9745323-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2017-08-29 | — | — | US | disclosed |
| US-9745323-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2017-08-29 | — | — | US | disclosed |
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2015-08-13 | — | — | US | disclosed |
| EP-2881397-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | Kyoto University (JP) | 2015-06-10 | — | — | EP | disclosed |
| EP-2881397-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | Kyoto University (JP) | 2015-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | VHL, TP53, COMT | PIM1 1202/4885MEN1 31/4885RAB9A 2200/4885 |
| US-20170355715-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | VHL, TP53, COMT | PIM1 1202/4885MEN1 31/4885RAB9A 2200/4885 |
| US-10017524-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | VHL, TP53, COMT | PIM1 1202/4885MEN1 31/4885RAB9A 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.